News

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly Weight-Loss Pill Trial Disappoints, Offsetting Solid Profit and Sales

Results from a late-stage trial of Eli Lilly's experimental weight-loss pill were disappointing, sending shares of the ...

Orforglipron: What to Know About Eli Lilly’s New Weight Loss Pill for Obesity

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.
Devdiscourse11d

Lilly's Weight Loss Pill Falls Short of Novo's Wegovy in Key Study

Eli Lilly's GLP-1 pill, orforglipron, led to 12.4% weight loss in a 72-week study, falling short of Novo Nordisk's Wegovy.

Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Eli Lilly: A Textbook Insider Buying Play

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Weight-loss drug Wegovy launches in South Africa

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

Novo Nordisk debuts Wegovy in South Africa as weight-loss drugs race gathers pace

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Lilly Signs $1.3 Billion Deal to Discover Obesity Medicines Using AI

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...